Non-randomized, Sequential, Fixed-sequence Evaluation of Prototype Dolutegravir Liquid Formulations Versus 5mg Dolutegravir Dispersible Tablets Following Single-dose Fasted-state Administrations to Normal Healthy Adult Participants
Latest Information Update: 03 Aug 2020
At a glance
- Drugs Dolutegravir (Primary) ; Dolutegravir (Primary) ; Dolutegravir
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
- 20 Sep 2019 Status changed from active, no longer recruiting to completed.
- 19 Jun 2019 Planned End Date changed from 7 Jun 2019 to 8 Jul 2019.
- 19 Jun 2019 Planned primary completion date changed from 7 Jun 2019 to 8 Jul 2019.